These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 10344754)
21. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide. Chung SW; Cohen EP; Kim TS Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380 [TBL] [Abstract][Full Text] [Related]
22. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396 [TBL] [Abstract][Full Text] [Related]
23. Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ. Rafiee M; Kanwar JR; Berg RW; Lehnert K; Lisowska K; Krissansen GW Cancer Gene Ther; 2001 Dec; 8(12):974-81. PubMed ID: 11781660 [TBL] [Abstract][Full Text] [Related]
24. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650 [TBL] [Abstract][Full Text] [Related]
25. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40. Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328 [TBL] [Abstract][Full Text] [Related]
26. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958 [TBL] [Abstract][Full Text] [Related]
27. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. Liu A; Hu P; Khawli LA; Epstein AL J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338 [TBL] [Abstract][Full Text] [Related]
28. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231 [TBL] [Abstract][Full Text] [Related]
29. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Wen XY; Mandelbaum S; Li ZH; Hitt M; Graham FL; Hawley TS; Hawley RG; Stewart AK Cancer Gene Ther; 2001 May; 8(5):361-70. PubMed ID: 11477456 [TBL] [Abstract][Full Text] [Related]
30. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. Tarte K; Zhang XG; Legouffe E; Hertog C; Mehtali M; Rossi JF; Klein B J Immunol; 1999 Jul; 163(1):514-24. PubMed ID: 10384156 [TBL] [Abstract][Full Text] [Related]
31. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. Merritt RE; Yamada RE; Crystal RG; Korst RJ J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342 [TBL] [Abstract][Full Text] [Related]
32. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Lang S; Atarashi Y; Nishioka Y; Stanson J; Meidenbauer N; Whiteside TL Cell Immunol; 2000 May; 201(2):132-43. PubMed ID: 10831322 [TBL] [Abstract][Full Text] [Related]
33. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Hodge JW; Schlom J Cancer Res; 1999 Oct; 59(20):5106-11. PubMed ID: 10537283 [TBL] [Abstract][Full Text] [Related]
34. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Liu A; Hu P; Khawli LA; Epstein AL Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313 [TBL] [Abstract][Full Text] [Related]
35. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. LaTemple DC; Abrams JT; Zhang SY; Galili U Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604 [TBL] [Abstract][Full Text] [Related]
36. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination. Zhou ZF; Peretz Y; Chang Y; Miao DS; Li X; Prud'homme GJ Cancer Gene Ther; 2003 Jun; 10(6):491-9. PubMed ID: 12768195 [TBL] [Abstract][Full Text] [Related]
37. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. Blanco B; Holliger P; Alvarez-Vallina L Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444 [TBL] [Abstract][Full Text] [Related]
38. B7.1 costimulation increases T-cell proliferation and cytotoxicity via selective expansion of specific variable alpha and beta genes of the T-cell receptor. Chan AK; Goedegebuure PS; von Bernstorff W; Carritte AL; Chung M; Stewart RA; Montgomery L; Spanjaard RA; McKenzie AB; Eberlein TJ Surgery; 2000 Mar; 127(3):342-50. PubMed ID: 10715992 [TBL] [Abstract][Full Text] [Related]
39. A triad of costimulatory molecules synergize to amplify T-cell activation. Hodge JW; Sabzevari H; Yafal AG; Gritz L; Lorenz MG; Schlom J Cancer Res; 1999 Nov; 59(22):5800-7. PubMed ID: 10582702 [TBL] [Abstract][Full Text] [Related]
40. Concurrent induction of T-cell activation and apoptosis of osteosarcoma cells by adenovirus-mediated B7-1/Fas chimeric gene transfer. Tsuji H; Kawaguchi S; Wada T; Nagoya S; Inobe M; Yagita H; Okumura K; Yamashita T; Uede T Cancer Gene Ther; 2003 Sep; 10(9):717-25. PubMed ID: 12944991 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]